.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Modern pharmaceutical manufacturing faces significant hurdles regarding drug-container interactions. Specifically, traditional vial stopper coatings like polydimethylsiloxane often shed particles into liquid formulations. These particles may compromise the quality and safety of delicate protein-based drugs. Consequently, researchers investigated a new method using aerosol-assisted cold plasma. This innovative process deposits a poly(MPC-co-BMA) copolymer directly onto the elastomeric stoppers.
Moreover, the study used a robust factorial design to optimize the vial stopper coatings and deposition parameters. Analysts employed advanced techniques like Scanning Electron Microscopy (SEM) and Raman imaging to verify the coating presence. Notably, the Raman imaging monitored the attenuation of inherent titanium dioxide signals from the stoppers. Therefore, they could map the coating uniformity without destroying the samples. This approach ensures that the protective layer remains consistent across the entire surface.
Furthermore, compatibility tests using a model bovine serum albumin formulation showed impressive results. The new poly(MPC-co-BMA) coating performed just as well as expensive commercial fluoropolymer options. Additionally, it significantly reduced the risk of polymer leaching compared to standard silicone oil treatments. Consequently, this aerosol-assisted cold plasma technique offers a promising future for pharmaceutical packaging. Ultimately, these findings provide a safer and more efficient alternative for storing high-value biologics.
These coatings use a biomimetic copolymer that reduces protein adsorption and prevents the leaching of chemicals from the rubber stopper into the drug, maintaining product purity.
Cold plasma allows for the application of high-performance coatings at room temperature. This protects heat-sensitive materials like rubber stoppers from damage during the manufacturing process.
While initial tests with bovine serum albumin are promising, further studies are necessary to confirm compatibility with a broader range of specific therapeutic proteins and formulation buffers.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional manufacturing guidelines. Refer to the latest local and national guidelines for clinical practice.
References
Downey JD et al. Application of a phosphorylcholine-based copolymer, poly(MPC-co-BMA) on vial stoppers using a cold plasma deposition process. Pharm Dev Technol. 2026 Mar 29. doi: 10.1080/10837450.2026.2649645. PMID: 41904960.
Ishihara K. Biomimetic polymers with phosphorylcholine groups as biomaterials for medical devices. Front Bioeng Biotechnol. 2021;9:747231.
Cools P et al. Cold plasma surface modification of biodegradable polymers. Surface and Coatings Technology. 2018;344:630-643.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a cold plasma method to coat vial stoppers with poly(MPC-co-BMA), improving protein stability and reducing leachable contamination....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
